The impact of center accreditation on hematopoietic cell transplantation (HCT)

被引:0
|
作者
S Marmor
J W Begun
J Abraham
B A Virnig
机构
[1] School of Medicine,Division of Health Policy & Management
[2] University of Minnesota,undefined
[3] School of Public Health,undefined
[4] University of Minnesota,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
There are two voluntary center-accrediting organizations in the USA, the Foundation for the Accreditation of Cellular Therapy (FACT) and core Clinical Trial Network (CTN) certification, that are thought to improve and ensure hematopoietic cell transplantation (HCT) center quality care and certify clinical excellence. We sought to observe whether there are differences in outcomes between HLA-matched and -mismatched HCT by CTN and FACT status. Using the 2008–2010 Center for International Blood & Marrow Transplant Research data we created three center categories: non-FACT centers (24 centers), FACT-only certified centers (106 centers) and FACT and core clinical trial network (FACT/CTN) certified centers (32 centers). We identified patient characteristics within these centers and the relationship between FACT certification and survival. Our cohort consisted of 12 993 transplants conducted in 162 centers. After adjusting for patient and center characteristics we found that FACT/CTN centers had consistently superior results relative to non-FACT and FACT-only centers (P<0.05) especially for more complex HCT. However, non-FACT centers were comparable to FACT-only centers for matched related and unrelated patients. Although FACT status is an important standard of quality control that begins to define improved OS, our results indicate that FACT status alone is not an indicator for superior outcomes.
引用
收藏
页码:87 / 94
页数:7
相关论文
共 50 条
  • [21] Single Center Retrospective Analysis of Outcomes Following Hematopoietic Cell Transplantation (HCT) for Primary Immune Deficiency (PID)
    Ballantyne, Elizabeth Blair
    Koptik, Karina Danner
    Philoctete, Debra
    Stoelinga, Mary
    Powers, Kimberly
    Votaw, Sarah
    Marshall, Connie
    Schneiderman, Jennifer
    Duerst, Reggie E.
    Chaudhury, Sonali
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [22] THE FIRST HEMATOPOIETIC CELL TRANSPLANTATION (HCT) ACTIVITY IN UZBEKISTAN AND IMPORTANT ROLE OF TRAINING IN HCT NURSING
    Kocubaba, S.
    Adibelli, G.
    Citlak, K.
    Kilinc, A.
    Kayikci, O.
    Tekgunduz, A. I. E.
    Altuntas, F.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S526 - S526
  • [23] Clinical impact of a prospective, sequential diagnostic approach for the study of pulmonary infiltrates in Hematopoietic Cell Transplantation (HCT).
    Rovira, M
    Rañó, A
    Carreras, E
    Danés, C
    González, J
    Fernández-Avilés, F
    Torres, A
    Montserrat, E
    BONE MARROW TRANSPLANTATION, 2001, 27 : S47 - S47
  • [24] THE IMPACT OF DONOR TYPE AND ABO INCOMPATIBILITY ON TRANSFUSION REQUIREMENTS AFTER NONMYELOABLATIVE HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
    Wang, Z.
    Sorror, M. L.
    Leisenring, W.
    Schoch, G.
    Maloney, D.
    Sandmaier, B. M.
    Storb, R.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S261 - S262
  • [25] Hematopoietic cell transplantation (HCT) therapy and the risk heart failure development
    Rispler, S.
    Henig, I.
    Sholy, H.
    Hammerman, H.
    Abassi, Z.
    Aronson, D.
    Zuckerman, T.
    EUROPEAN JOURNAL OF HEART FAILURE, 2013, 12 : S180 - S180
  • [26] Interaction of Age and Comorbidities and Their Impacts on Hematopoietic Cell Transplantation (HCT) Outcomes
    Ostronoff, Fabiana
    Storer, Barry
    Storb, Rainer
    Bhatia, Smita
    Maziarz, Richard T.
    Pulsipher, Michael A.
    Maris, Michael T.
    Deeg, H. Joachim
    Martin, Paul J.
    Appelbaum, Frederick R.
    Maloney, David G.
    Sandmaier, Brenda M.
    Sorror, Mohamed L.
    BLOOD, 2011, 118 (21) : 305 - 306
  • [27] Third party fecal microbiota transplantation (FMT) in hematopoietic cell transplantation (HCT) recipients
    DeFilipp, Z.
    Jenq, R.
    Smith, M.
    Li, S.
    Mahabamunuge, J.
    Dagher-Mansour, Z.
    Kempner, M.
    Brown, J.
    Oefner, P.
    Slingerland, A.
    El-Jawahri, A.
    Holler, E.
    Mansour, M.
    Hohmann, E.
    Chen, Y-B
    BONE MARROW TRANSPLANTATION, 2017, 52 : S85 - S86
  • [28] COGNITIVE PERFORMANCE AND IMPAIRMENT PRIOR TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
    Nelson, Ashley M.
    Gonzalez, Brian D.
    Sutton, Steven K.
    Cessna, Julie M.
    Rose, Melissa
    Booth-Jones, Margaret
    Field, Teresa
    Jacobsen, Paul B.
    Jim, Heather
    ANNALS OF BEHAVIORAL MEDICINE, 2015, 49 : S221 - S221
  • [29] HCT Frailty Scale for adults undergoing allogeneic hematopoietic cell transplantation
    Salas, M. Q.
    Atenafu, E. G.
    Al-Shaibani, E.
    Bascom, O.
    Wilson, L.
    Chen, C.
    Pasic, I.
    Law, A. D.
    Lam, W.
    Kim, D. D. H.
    Gerbitz, A.
    Viswabandya, A.
    Lipton, J. H.
    Michelis, F. V.
    Mattsson, J.
    Alibhai, S.
    Kumar, R.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 79 - 80
  • [30] RIFAXIMIN TO PREVENT BLOODSTREAM INFECTIONS IN PEDIATRIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
    Teherani, Mehgan
    Gillespie, Scott
    Pratte, Zoe
    Banksota, Samridhi
    Gulick, Dalia
    Djeddar, Naima
    Chahroudi, Ann
    Horan, John
    Gibson, Gregory
    Qayed, Muna
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S105 - S105